GammaCan International to Present at the 8th Annual Rodman & Renshaw Global Healthcare Conference in New York City

  
    
  
  
    
      GammaCan International, Inc. (OTC BB: GCAN), a developer of 
      immunotherapies to treat melanoma and other cancers, today announced 
      that Patrick Schnegelsberg, Chief Executive Officer, will provide a 
      company overview and highlight GammaCan’s 
      recent developments at the Rodman & Renshaw 8th Annual Healthcare 
      Conference, at 11:00 AM EST on November 8th at the New York Palace Hotel 
      in New York City.
    
    
      Mr. Schnegelsberg will provide a company overview along with highlights 
      on recent progress with VitiGam, GammaCan's lead program under 
      development to treat stage III and IV melanoma and an update on the GCAN 
      101 Phase II trial.
    
    
      A live Webcast of Mr. Schnegelsberg’s 
      presentation will be available at http://www.wsw.com/webcast/rrshq10/gcan.ob 
      and also on GammaCan’s website at http://www.gammacan.com 
      under the "Investor Information/Webcasts" link. The Webcast will be 
      archived for approximately 90 days.
    
    
      About VitiGam:
    
    
      VitiGam is GammaCan's second generation intravenous IgG-based product 
      and a first-in-class anti-cancer immunotherapy. GammaCan plans on having 
      VitiGam to enter phase I/II testing under a US IND in the near future 
      after it recently held a pre-IND meeting with the FDA. VitiGam is being 
      designed to target metastatic melanoma patients with Stage III and IV 
      melanoma. VitiGam is an IgG product that is different from standard 
      IgGs: It is manufactured from the plasma of donors with vitiligo, a 
      benign autoimmune skin condition affecting up to 2% of the general 
      population. GammaCan scientists have shown that this "enriched" vitiligo 
      IgG (VitiGam) contains potent anti-melanoma activity in both in vitro 
      and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to 
      provide (1) anti-melanoma activity directed specifically against 
      malignant melanoma cells and (2) non-specific anti-cancer activity - as 
      is the case with IgG in general.
    
    
      About GammaCan:
    
    
      GammaCan is focusing on the commercialization of an innovative 
      anti-cancer immunotherapy to treat metastatic cancer. GammaCan's 
      platform is based on IgG, a safe, relatively non-toxic human 
      plasma-based product, currently used to treat a variety of immune 
      deficiencies and autoimmune diseases. IgG works by strengthening the 
      patient's immune system. Many experts currently view immunotherapy as a 
      future alternative to today's standard chemotherapy. GammaCan is 
      developing VitiGam, its second generation program. VitiGam is an IgG 
      derived from the plasma of vitiligo donors and is being developed to 
      treat malignant melanoma. GammaCan owns, and has applied for US patent 
      protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
    
    
      For more information about GammaCan visit www.GammaCan.com 
      or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 
      738-2616 or toll free 1-866-308-0396 (from North America).
    
    
      Safe Harbor Statement:
    
    
      Statements in this document that are not purely historical are 
      forward-looking statements. Forward-looking statements in this release 
      include statements regarding the commercialization of an anti-cancer 
      immunotherapy and the Company developing the boosting of cancer 
      patients' immune systems with IgG into an effective treatment. Actual 
      outcomes and the Company's actual results could differ materially from 
      those in such forward-looking statements. Factors that could cause 
      actual results to differ materially include risks and uncertainties such 
      as the inability to finance the planned development of the technology, 
      unforeseen technical difficulties in developing the technology, the 
      inability to obtain regulatory approval for human use, competitors' 
      therapies proving more effective, cheaper or otherwise preferable for 
      consumers, inability to market the product we produce, among other 
      factors, all of which could among other things, delay or prevent product 
      release or cause our company to fail. For further risk factors see the 
      risk factors associated with other early state medical research and 
      development companies filed with the SEC on Edgar.
    
  
GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies to treat melanoma and other cancers, today announced
that Patrick Schnegelsberg, Chief Executive Officer, will provide a
company overview and highlight GammaCan's recent developments at the
Rodman & Renshaw 8th Annual Healthcare Conference, at 11:00 AM EST on
November 8th at the New York Palace Hotel in New York City.

   Mr. Schnegelsberg will provide a company overview along with
highlights on recent progress with VitiGam, GammaCan's lead program
under development to treat stage III and IV melanoma and an update on
the GCAN 101 Phase II trial.

   A live Webcast of Mr. Schnegelsberg's presentation will be
available at http://www.wsw.com/webcast/rrshq10/gcan.ob and also on
GammaCan's website at http://www.gammacan.com under the "Investor
Information/Webcasts" link. The Webcast will be archived for
approximately 90 days.

   About VitiGam:

   VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan plans
on having VitiGam to enter phase I/II testing under a US IND in the
near future after it recently held a pre-IND meeting with the FDA.
VitiGam is being designed to target metastatic melanoma patients with
Stage III and IV melanoma. VitiGam is an IgG product that is different
from standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of the
general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models. Thus,
GammaCan expects VitiGam to provide (1) anti-melanoma activity
directed specifically against malignant melanoma cells and (2)
non-specific anti-cancer activity - as is the case with IgG in
general.

   About GammaCan:

   GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).

   For more information about GammaCan visit www.GammaCan.com or call
the company's headquarters in Kiryat Ono, Israel at [phone]
or toll free 1-866-308-0396 (from North America).

   Safe Harbor Statement:

   Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, unforeseen technical difficulties in developing the
technology, the inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early state medical
research and development companies filed with the SEC on Edgar.